Moderna cash flow up big on COVID-19 vaccine upfront payments

• Moderna (NASDAQ:MRNA) Q3 results:
• Grant & collaboration revenue: $157.9M (+828.8%).
• Net loss: ($233.6M) (-89.6%); loss/share: ($0.59) (-59.5%).
• Cash flow ops (9 mo.): $762.7M (+311.9%).
• 2020 guidance: Cash flow ops: $$100M - 300M driven by customer deposits of ~$1.2B received ytd for mRNA-1273.
• Pipeline update:
• Infectious diseases:
• COVID-19 vaccine candidate mRNA-1273: Phase 3 30K-subject COVE study fully enrolled.
• Phase 3 study on CMV vaccine candidate mRNA-1647 should launch in 2021.
• First cohort in Phase 1 study of RSV vaccine candidate mRNA-1345 fully enrolled.
• Preparations for Phase 2 study of Zika virus vaccine candidate mRNA-1893 underway.
• Resumed dosing pediatric patients in Phase 1b de-escalation study of hMPV/PIV3 vaccine candidate mRNA-1653 following COVID-19 disruptions.
• Oncology:
• Dosing underway in Phase 2 study of OX40L (mRNA-2416), combined with AstraZeneca's Imfinzi (durvalumab), in ovarian cancer.
• Rare diseases
• Granted Rare Pediatric Disease Designation in U.S. for mRNA-3705 for methylmalonic acidemia (MMA), an inherited disorder in which the body is unable to properly metabolize certain proteins and fats.
• Start-up activities underway for Phase 1/2 study of mRNA-3927 for propionic acidemia (PA), an inherited disorder in which the body is unable to properly process certain parts of proteins and lipids. 
• https://seekingalpha.com/news/3628162-moderna-cash-flow-up-big-on-covidminus-19-vaccine-upfront-payments-shares-up-2